First Name: Mohammad Hossein Family Name: Alimohammadian ...

1. Personal information:
CURRICULUM VITAE
First Name: Mohammad Hossein
Family Name: Alimohammadian
Birth Place: Iran, Ardabil Birth Date : 8 May 1946
Nationality: Iranian
Academic Rank: Professor
Address: Department of Immunology,
Pasteur Institute of Iran, Pasteur Avenue 69., Tehran, Iran.
Tel: (0098 21) 6696 88 57
Fax: (009821) 6646 51 32
E-mail mhalimohammadian@yahoo.com
2. EDUCATION:
Doctor of Pharmacy, School of Pharmacy, Tehran University, 1964-1970
Medical diagnostic laboratory specialist (MDLS), School of Medicine, Tehran University,
1975-1980.
Post-doctorial short courses in advance immunology: a) WHO Sponsored Course in
Immunology and Molecular Biology Applied for Infectious Diseases, Institute of
Biochemistry, Lausanne University, Switzerland, September 13 - October 21, 1989; b) a
training and reseach course in practical immunology, Institue of Biochemistry, Lausanne
University, Switzerland, October 22 -December 9, 1989, c) a training course in
hybridoma technoloy, SDS-PAGE, Immunobloting, and ELISA, Dept. of Vaccine, State
Serum Institute, Copenhagen, December 11, 1989 - March 14, 1990, and d) a training and
research course in T cell proliferation assay, human T-cell cloning and cytokine bioassay,
Dept. of Clinical Microbiology, University of Copenhanen, Denmark, September 2 -
October 29, 1991.
Sabbatical Course in molecular biology and genetic: School of Biological Sciences,
University of Liverpool, Liverpool, UK, February 17, 2004, Feb 16, 2005.
3. Theses:
Parm D thesis: Analysis of amino acids in nutritional proteins by gas chromatography,
Pharmacy doctorate, Supervisor: Dr. Farrahi, School of Pharmacy, Tehran University,
Tehran, 1969-1970.
MDLS thesis: Studies of the effect of levamisol on the immune responses of mice infected
with Leishmania. Supervisor: Dr Farrokh Modabber, School of public Health, Tehran
University, 1978-1980.
4. Honors and Awards:
1

4.1. A research training grant awarded by UNDP/World Bank/ WHO, Special Programme
for Research and Training in Tropical Diseases (TDR) for 6 months in Switzerland and
Denmark, September 1989 - March 1990.
4.2. Kharazmi International Festival Award: awarded by President of Islamic Republic of
Iran. Organized by Iranian Scientific and Industrial Researchs Organization, Ministry
of Culture and High Education, February 1996.
4.3. Research third grade Medal, awarded by President of Islamic Republic of Iran, October
2004.
5. Projects completed:
5.1. Study on the role of regulatory T and Th-17 cells in symptomatic and asymptomatic
clinical forms of Leishmania major infection (1388-1391.
5.2. Cloning and expression of recombinant protein of ferroportin and its application
in treatment of susceptible mice to Leishmania major(1388-1391).
5.3. The effect of Naloxone on immunological responses of BALB/c mice infected with
Leishmania major (1387-1388).
5.4. Clinical trial for comparison of two Leishmania antigens of QuantiFERON with
leishmanin skin test on individuals with history of leishmaniasis in Iran (87-88).
5.5. Cloning, expression and immunologic evaluation of Leishmania infantum Nuclease
(P4) (1385-1388).
5.6. Polymorphism in cytokine genes in different clinical forms of cutaneous Leishmaniasis.
Pasteur Institute of Iran, 2006-2008.
5.7. Correlation of anaemia associated with Trypanosoma congolense infection in susceptible and
resistant mice strains via expression of IREG1 and IL-6 genes. School of Biological Sciences,
University of Liverpool, UK, 2004-2005.
5.8. Identification of Leishmania species and sub-species in endemic areas of
leishmaniasis by biochemical, immunological and molecular
methods.
Pasteur Institute of Iran, 2002- 2008.
5.9. Isolation and evaluation the immunogenicity of membrane proteins of L. major
amastigotes in peripheral mononuclear cells of healed leishmaniasis individuals,
Pasteur Institute of Iran, 2002-2008.
5.10. Collection, cataloging, characterization and storage of L. major isolates, TDR-Pasteur
Institute of Iran, Tehran, 1999-2002.
5.11. Study on immunogenicity of procyclic promastigotes and amastigotes of L. major in
human and mice model, Pasteur Institute of Iran, 1999-2001.
5.7. Identification of Leishmania major fraction responsible for DTH. Pasteur Institute,
Tehran, Iran, 1998-2001.
5.12. Evaluation of the immunogenicity of three doses of killed Leishmania major vaccine
in healthy volunteers, Center for Research and Training on Skin Diseases & Leprosy,
and Pasteur Institute of Iran, 1999-2001.
5.13. Study on adjuvanity effect of Leishmania major on the immune responses of mice
immunized with ovalbumin. Pasteur Institute, Tehran, Iran, 1998-2000.
5.14. Study on T cell phenotypes and cytokine profile in patients with cutaneous
leishmaniasis and recovered cases, in endemic areas of Kashan and Tehran. Pasteur
Institute, Tehran, Iran, 1996-1998.
2

5.15. Preparation and evaluation of soluble and phenol leishmanin. TDR-Pasteur Institute,
Tehran, Iran, 1995-1999.
5.16. Semi-industrial production of Leishmanin and its evaluation in endemic areas of
cutaneous leishmaniasis, Pasteur Institute of Iran, 1996-1997.
5.17. Preparation of killed Leishmania major vaccine for vaccine studies. TDR-Pasteur
Institute, Tehran, Iran, 1994-1996.
5.18. Preparation and evaluation of a standard soluble Leishmania major antigen in semiindustrial
scale, TDR- Pasteur Institute, Tehran, Iran, 1990-1994.
5.19. Preparation of skin test antigen from Leishmania major for use in human for
diagnostic and experimental purposes. TDR - Pasteur Institute, Tehran, Iran, 1987-
1990.
Current project:
Efficacy and Immunogenicity trial of Alum precipitated autoclaved Leishmania
major (Alum-ALM) vaccine mixed with BCG along with Imiquimod adjuvant in
healthy dogs of Kala-azar endemic areas (north-west of country)
6. Grants:
6.1 World Health Organization, TDR. Preparation and evaluation of standard leishmanin.
for five different grants, 1987-2002.
6.2. World Health Organization, TDR. Preparation and evaluation of killed L. major
vaccine. from 1993-1994.
6.3. World Health Organization, TDR. Collection, cataloging, characterization and storage
of L. major isolates. 1999-2002.
7. Theses directed:
7.1. Designing, Construction and Evaluation of a Polyepitope DNA Plasmid against Acute
Myelogenous Leukemia. Major, Pasteur Institute of Iran, Tehran 2009-2012.
7.2 Cloning and expression of fish ferroportin (IREG1) and study of its influence on
Anemia treatment of BALAB/c mic infected with Leishmania major. PhD, Major,
Islamic Azad University, Tehran 2008- 2010.
7.3. Producing and analysis the effect of recombinant hepcidin on proliferation of
NS-1 cell line and J774 A.1 infected with Leishmania major. PhD, Major, Isfahan
University of Medical science, Isfahan, 2008-2010.
7.4. Comparative studies of Th1 and Th2 cytokines mRNA by RT-PCR in mice inoculated
with different strains of Leishmania major. MS, Major, Islamic Azad University,
Tehran, 2007-2009.
3

7.5. Separation and characterization of glycoconjugate from Iran Leishmania major. PhD,
Minor, Institute of Biochemistry and Biophysics, University of Tehran, 2004-2006.
7.6. Cloning, expression and immunological evaluation of P4 protein of Leishmania major.
PhD, First Major, Pasteur Institute of Iran, Tehran, Iran, 2002-2005.
7.7. Characterization of different strains of Leishmania major in Iran and study on
immunogenicity and pathogenicity of various strains to select most immunogenic
strain for vaccine, PhD, Major, Pasteur Institute of Iran, Tehran, 2000-2003.
7.8. Preparation and characterization of monoclonal antibody against amastigote stage of
Leishmania major and studing it's role in immunotherapy of infected BALB/c mice.
PhD, First Major, Pasteur Institute of Iran, Tehran, Iran, 1998-2002.
7.9. Investigation on production of gamma interferon, interleukine-12 and Interleukine-10
cytokines in response to different forms (procyclic, and axenic amastigotes) of
Leishmania major parasites, First Major, Tehran University of Medical Sciences,
Tehran, Iran, 1998-2001.
7.10. Investigation of cellular immunity in patients with cutaneous leishmaniasis and
recovered individuals. Second Major, School of public Health, Tehran University of
Medical Sciences, Tehran, 1997-2000.
7.11. Expression of glycoprotein 63 (Gp63) gene of Leishmania major in E. coli. Second
Major, Pasteur Institute of Iran, Tehran, Iran, 1998-1999
7.12. Purification of IgE from the serum of atopic patients, production of monoclonal
antibody for designing ELISA kit, Minor, University of Tarbiat Modarres, Tehran,
1997-1999.
7.13. Preparation and characterization of murine monoclonal antibodies against major
subsets of hepatitis B surface antigen, Major, Pasteur Institute of Iran, Tehran, Iran,
1996-1999.
7.14 Biochemical analyses and evaluation of immunogenic fraction of Leishmania major
amastigotes. First Major, Pasteur Institute of Iran, Tehran, Iran, 1994-1996.
7.15. Immunological evaluation of Leishmania major antigenic fractions by biochemical
methods. Minor, University of Tarbiat Modarres, Tehran, 1994-1996.
Also another 16 theses of MS and MSc have been supervised.
8. Books:
Manual of Laboratory Immunology, Miller, LE, Ludke HR, Peacock JE, and Tomar
RH. Translated by Alimohammadian, MH and Mahmoodzadeh-Niknam, H,
Publisher: Negareh, from English to farsi, 1995.
9. Teaching:
Ph.D course in Advance Immunology, Pasteurr Institute of Iran 1999- present
- M.Sc course in Immunology of infectious diseases, Pasteurr Institute of Iran 1999-
present
-Advanced Immunology for PhD parasitology students, Iran University of Medical
Sciences, 2001-2003
- Immunology for PhD students of biotechnology, IBB, Tehran University , 2007
- Molecular Immunology for PhD students of biotechnology, Pasteur Institute of Iran,
2010- 2011
4

10. Articles:
1.
1. Asadpour A, Riazirad F, Khaze V, Ajdary S and Alimohammadian MH. (2013) Distinct
strains of Leishmania major induce different cytokine mRNA expression in draining lymph
node of BALB/c mice. Parasite Immunology 35: 42-50.
2. Mahmoudzadeh-Niknam H, Ajdary S, Riazirad F, Mirzadegan E, Rezaeian AH, Khaze
V and Alimohammadian MH. (2012) Molecular epidemiology of cutaneous leishmaniasis
and heterogeneity of Leishmania major strains in Iran. Trop Med Int Health, 17:
1335-1344.
3. Alimohammadian MH, Jones SL, Darabi H, Riazirad F, Ajdari S, Shabani A, Rezaee
M, Mohebali M, Hosseini Z, and Modabber F. (2012) Assessment of Interferon-γ levels
and leishmanin skin test results in persons recovered for leishmaniasis. Am J Trop Med
Hyg 87: 70-75.
4. Saeedi NS, Sholrgozar MA, Mousavi A, Azadmanesh K, Nomani A, Apostolopoulos V,
Day S, Amanzadeh A, Alimohammadian MH. (2012) Simultaneous immunization with
a Wilms' Tumour 1 epitope and its ubiquitin fusion results in enhanced cell mediated
immunity and tumour rejection in c57BL/6 mice. Mol Immunol 51: 325-331.
5. Rafiei A, Fatemi SMR, Jamili Sh, Ajdary S, Riazi-rad F, Memarnejadian A and
Alimohammadian MH (2012) Cloning, expression and characterization of zebra fish
ferroportin in Hek 293T cell line. Iranian J publ Health, 41: 79-86.
6. Yazdani Y, MM Sadegi H, Alimohammadian MH, Andalib A, Moazen F, Rezaei A.
(2011) Expresion of an innate immune element (mouse Hepcidin) in baclovirus
expression system and comparison of its function with synthetic human Hepcidin-25.
Iranian J of Parmaceutical Research, 10: 559-568..
7. Rahimi-Moghaddam P, Ebrahimi SA, Ourmazdi H, Selseleh M, Karjalian M, Haj-
Hassani G, Alimohammadian MH, Mahmoudian MShafiei M. (2011). In vitro and in
vivo activities of Peganum harmala extract against Leishmania major. J Res Med Sci,
16: 1032-1039.
8. Farajnia S, Rahbarnia L, Maleki zanjani B, Alimohammadian MH, Abdoli Sh, Beh-
Pajooh A, Saeedi NMontazer Saheb S. (2011) Molecular Cloning and characterization of
P4 Nuclease from Leishmania infantum. Enzyme Research, Epub 2011 Jun 28.
9. Ajdary S, Ghamilouie MM, Alimohammadian MH, Riazi-Rad F, Pakzad SR. (2011) Tolllike
receptor 4 polymorphisms predispose to cutaneous leishmaniasis. Microbes and
Infection, 13: 226-231.
10. Mahmoodzadeh-Niknam H, Abrishami F, Doroudian M, Moradi M, Alimohammadian
MH, Parvizi P, Hatam GhR, Mohabali M, Khalaj V. (2011) The problem of mixing up
of Leishmania isolates in the Laboratory: suggesting of ITS1 gene sequencing for
verification of species. Iranian J Parasitol, 6: 41-48.
11. Alimohammadian MH, Darabi H, Ajdary S, Khaze V, Torkabadi E. (2010)
Genotypically distinct strains of Leishmania major display diverse clinical and
immunological patterns in BALB/c mice. Infect Genet Evol. 10: 969-75.
12. Mahmoodzadeh-Niknam H, Abrishami F, Doroudian M, Moradi M, Alimohammadian
MH, Parvizi P. (2010) Complete conservation of an immunogenic gene (lcr1) in
5

Leishmania infantum and Leishmania chagasi isolated from Iran, Spain and Brazil. J
Vector Borne Dis 47: 204-210.
13. Akhavan AA, Yagobi-Ershadi MR, Mirhendi H, Alimohammadian MH, Rassi Y,
..Khamesipour A. et al (2010). Molecular epizootiology of rodent leishmaniasis in a
hyperendemic area of Iran. Iranian J publ Health 39: 1-7.
14. Ajdary S, Ghamilouie MM, Alimohammadian MH, Hosseini M, Pakzad SR. (2010)
Lack of association of Toll-like receptor 2 Arg753Gln with cutaneous
leishmaniasis.Parasitol Int. 59: 466-68.
15. Akhavan AA, Mirhendi H, Khamesipour A, Alimohammadian MH, Rassi Y, Bates P,
Kamhawi S, Valenzuela JG, Arandian MH, Abdoli H, Jalali-Zand N, Jafari R,
Shareghi N, Ghanei M, Yaghoobi-Ershadi MR.(2010) Leishmania species: Detection
and identification by nested PCR assay from skin samples of rodent reservoirs, Exp
Parasitol. 126: 552-6.
16. Akhavan AA, Yaghoobi-Ershadi MR, Khamesipour A, Mirhendi H, Alimohammadian
MH, et als (2010) Dynamics of Leishmania infection rates in Rhombomys opimus
(Rodentia: Gerbillinae) population of an endemic focus of zoonotic cutaneous
leishmaniasis in Iran.Bull Soc Pathol Exot, 103(2):84-9.
17. Kavoosi G, Ardestani SK, Kariminia A, Alimohammadian MH.(2010) Leishmania
major lipophosphoglycan: discrepancy in Toll-like receptor signaling. Exp Parasitol,
124(2):214-8.
18. Ajdary S, Riazi-rad F, Alimohammadian MH, Pakzad SR. Immune response to
Leishmania antigen in anthroponotic cutaneous leishmaniasis. Journal of Infection
2009, 59: 139-143.
19. Noyes HA, Alimohammadian MH, Agaba M, Brass A, Fuchs H, Gailus-Durner V,
Hulme H, Iraqi F, Kemp S, Rathkolb B, Wolf E, de Angelis MH, Roshandel D,
Naessens J. Mechanisms controlling anaemia in Trypanosoma congolense infected
mice. Plos One 2009, 4: 1-13.
20 Farajnia S, Darbani B, Babaei H, Alimohammadian MH, Mahboudi F, Gavgani AM.
Development and evaluation of Leishmania infantum rK26 ELISA for serodiagnosis of
visceral leishmaniasis in Iran. Parasitology 2008, 19:1-7.
21. Kavoosi G, Ardestani SK, Kariminia A, Zeinali M, Alimohammadian MH. Leishmania
major: Effects of proteophosphoglycan on reactive oxygen species, IL-12, IFN-gamma
and IL-10 production in healthy individuals. Exp Parasitol. 2008 , 120: 62-66.
22. Alimohammadian MH, Darabi H, Malekzadeh Sh, Mahmoodzadeh-Niknam H, Ajdary S,
Khamesipour A, Bahonar A, Mofarrah A. Exposure to Leishmania major modulates the
proportion of CD4+ T cells without affecting cellular immune responses. Microbiology and
Immunology 2007, 51: 1003-1011.
23. Tashakori M, Kuhls K, Al-Jawabreh A, Mauricio I, Schonian G, Farajnia S, Alimohammadian
MH. (2006) Leishmania major: Genetic heterogenecity of Iranian isolates by single-strand
conformation polymorphism and sequence analysis of ribosomal DNA internal transcribed
spacer. Acta Tropica 98: 52-58.
24. Khabiri AR, Bageri F, Alimohammadian MH, Assmar M, Nadaf SR. (2005) Leishmanin skin
test in guinea pig with a single purified protein of Leishmania major Exp Parasitol, 111: 239-
243.
25. Farajnia S, Mahboodi F, Ajdari S, Reiner NE, Kariminia A, and Alimohammadian MH. (2005).
Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to
Leishmania major amastigote class I nuclease with a predominant Th1-like response. Clin
Exp Immunol, 139: 498-505.
6

26. Farajnia S, Alimohammadian MH, Reiner NE, Karimi M, Ajdri S, Mahboudi F. (2004).
Molecular characterisation of a novel amastigote stage specific class I nuclease from
Leishmania major. Int. J. Parasitol., 34: 899-908.
27. Mirjalili A, Alimohammadian MH and Khabiri A. (2004). Improvement of Leishmania major
Amastigote ELISA test using various antigen-antibody dissociating agents and pepsin
degestion. Arch. Razi Ins. 57: 33-44.
28. Rezaeian A, Alimohammadian MH, Zeinali S. (2003). Microsatellie analysis of mouse TNF
and Cypla2 loci for polymorphism: detection and evaluation of genetic contamination. Scand.
J. Lab. Anim.Sci., 30:143-149.
29. Mirjalili A, Alimohammadian MH, Madani R. (2003). Presence of immunoglo-bulins on the
surface of lesion-drived amastigotes of Leishmania major as a tool for isolation of amastigote
stage from BALB/c mice. Iranian Biomedical Journal, 7: 155-160.
30. Tashakori M, Ajdari S, Kariminia A, Mahboudi F and Alimohammadian MH. (2003)
Chracterization of Leishmania species and L. major strains in different endemic areas of
cutaneous leishmaniasis in Iran. Iranian Biomedical Journal, 7: 43-50.
31. Alimohammadian MH, Khamesipour A, Darabi H, Firooz AR, Malekzadeh S, Bahonar A,
Dowlati Y, Modabber F. (2002) The role of BCG in human immune responses induced by
multiple injections of autoclaved Leishmania major as a candidate vaccine against
leishmaniasis. Vaccine 21: 174-180.
32. Darabi H, Abolhasani M, Kariminia A, Alimohammadian MH (2002) Expansion of γδ T cells
in patients infected with cutaneous leishmaniasis with and without glucantim therapy. The
Brazilian Journal of Infectious Diseases, 6: 258-262.
33. Alimohammadian MH, Darabi H, Kariminia A, Rivier D, Bovay P, Mauel J, Ajdary S, and
Kharasmi A. (2002) Adjuvant effect of Leishmania major promastigotes on the immune
response of mice to ovalbumin. Iranian Biomedical Journal, 6: 123-128.
34. Khabiri AR, Abolhasani M, Aslani S, Darabi H, Bageri F, and Alimohammadian MH.
(2001) Compositional changes of PBL population in Patients with chronic hepatitis B virus
infection. The Brazilian Journal of Infectious Diseases, 5: 345-351.
35. Kariminia A, Darabi H, Keyhani A, and Almohammadian MH. (2001). Induction of Th1
cytokines by live logarithmic promatigotes of L. major. Iranian Biomedical Journal, 5:15-20.
36. Malakaneh M, Rasaee MJ, Rahbanizadeh F, Madani R, Forozandeh MM, Khabiri AR,
Alimohammadian MH (2001) Chracterization of a monoclonal antibody against neopetrin
using an enzyme-linked immunosorbent assay with penicillinase as lable. Hybridoma 20: 117-
121.
37. Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, and Kharazmi A. (2000).
Comparison of the immune profile of nonhealing cutaneous leishmaniasis patients with those
with active lesions and those who have recovered from infection. Infection and immunity, 68:
1760-1764.
38. Kariminia A, Keyhani A, Asslanian S and Alimohammadian. (2000) Live logarithmic
phase promastigotes of Leishmania major induce high level of IFN-γ but lower level of IL-10
in whole blood culture of healthy individuals. Acta Medica Iranica, 38: 168-173.
39. Majidi J, Zavaran H, Hassan ZM, Alimohammadian MH. (2000) Production of monoclonal
antibody against human immunoglobulin E. Iranian Journal of Allergy, Asthma and
Immunology, 1:81-87.
40. Alimohammadian MH, Almasi H, Khabiri AR, Hatam GR, Karimi A, Mahboudi F,
Tehrani SM, Amirkhani A. (1999) Identification of species and characterization of an
outbreak of cutanous leishmaniasis in a new focus of Iran. Iranian Biomedical Journal, 3:31-
39.
41. Ajdary S, Eslami MB, Pakzad S, Alimohammadian MH. (1999) Cytokine production pattern
by different subtypes of T cells in cutaneous leishmaniasis. Iranian Journal of Medical
Sciences, 24:1-75.
7

42. Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Labaf Ghassem R,
Dowlati Y, Sharifi I, Aminjavaheri M, Shafiei A, Alimohammadian MH, Hashemi-
Fesharaki R, Nasseri K, Godal T, Smith G, Modabber F. (1998). A randomised,
double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic
cutaneous leishmaniasis in Iran.Vaccine, 17: 466-472.
43. Malekzadeh Sh., Hosseini SMH, Darabi H and Alimohammadian MH (1998). Partially
induced protection by a fraction of Leishmania major promastigotes against murine
leishmaniasis. Iranian Biomedical Journal, 2: 27-32.
44. Alimohammadian MH, Kojori ZF, Darabi H, Malekzadeh Sh, Yousefbeig M, Irvani-nia
F. (1997) Soluble leishmanin as an ideal reagent for skin testing in human leishmaniasis.
Iranian biomedical journal, 1: 39-47.
45. Khabiri AR, Alimohammadian MH, Shokri F. (1997). Preparation of monoclonal
antibodies against the common determinants of HBsAg. Iranian Journal of Medical Sciences,
22: 38-44.
46. Rafati S, Couty-Jouve S, Alimohammadian MH, Louis JA. (1997) Biochmical analysis
and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis.
Clinical and Experimental Immunology, 110: 203-211.
47. Rafati-Seyedi-Yazdi S, Couty-Jouve S, Alimohammadian MH, Dowlati Y. (1997).
Evaluation of cellular Immune response of recovered human cutaneous leishmaniasis to
amastigote soluble Leishmania major antigens. Medical Journal of Islamic Republic of
Iran, 11: 33 - 38.
48. Ajdari S, Hosseini SMH, and Alimohammadian MH, (1997). Recombinant IL-1 promottes
leishmaniasis in the susceptible mice. Microbiology and Immunology, 41: 281-283.
49. Mahmodzadeh Niknam H, Alimohammadian MH, Nasefat S, Amirkhani A. (1996). Effect
of mammalian ambient temperature on Leishmania major promastigotes: viability,
morphology and immunogenicity in BALB/c mice. Iranian Journal of Medical Sciences, 21:
125-129.
50. Bahar K, Dowlati Y, Shidani B, Alimohammadian MH, Khamecipour A, Ehsasi S,
Hashemi-Fesharaki R, Ale-Agha S, Modabber F. (1996). Comparative safety and
immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human
volunteers. Clinics in Dermatology,14: 489-495.
51. Niknam HM, Mansoori P, nikbin B, Deneshpajouh M, Amirkhani A, and Alimohammadian
MH, (1996). HLA Class I in Iranian psoriatic patients. Medical Journal of Islamic Republic
of Iran, 10: 37-41.
52. Alimohammadian MH. (1995). The role of immune cell interctions and cytokine network in
immunity against leishmaniasis. In: Immunology Update. Proceeding of the Third Iranian
Congress of Allergy & immunology, Shiraz University of Medical Sciences, Iran 1995,
Publisher: Iranian Journal of Medical Sciences, pp. 80-88.
53. Alimohammadian MH, Kivanjah M, Pak F, Gaznavi A, Kharazmi A: (1993). Evaluation of
the efficacy of Iran leishmanin and comparison with leishmanins form Wellcome (UK) and
Roma (Italy) in cured cutaneous leismaniasis patients. Transactions of the Royal Society of
Tropical Medicine and Hygiene, 87: 550-551.
54. Alimohammadian MH, Hakimi H, Nikseresht MH. (1993). The preparation and evaluation of
reference leishmanin from L. major for use in man for diagnostic and experimental purposes.
Med J Isla Rep Iran, 7:23-28.
55. Nobakht M, Simforoush N, Alimohammadian MH, Amir Ansari B, (1990). The Role of T
lymphocyte subpopulation in renal allograft rejection. Med J Isla Rep Iran, 4: 47-52.
56. Modabber F, Alimohammadian MH, Khamesipour A, Pourmand M, Kamali M, and Nasseri M.
(1980). Studies on the genetic control of visceral leishmaniasis in BALB/c mice by L. tropica.
In: Genetic Control of Natural Resistance and Malignancy, E Skamene, PAL Konashavens,
and M Landy (Eds). pp. 29-37.
8

57. Alimohammadian MH, and Modabber F. (1979). Preliminary studies of the effect of
levamisol on the immune response of mice infected with Leishmania. Iranian Journal of
public Health, 8: 71-85 (Farsi), 118-119 (English abstract).
Also 10 articles have been published in Farsi journals
15. Invention
In Iran: Preparation of Leishmanin reagent for diagnostic purposes
Submitted gene for NCBI NIH:
Seven new genes by following accession numbers:
AY079097: Leishmania major class I nuclease gene
AY487805: Leishmania donovani, class I nuclease mRNA
AY283793: Leishmania major strain MHOM/Ir/02/PIIDT1
AY260965: Leishmania major strain MHOM/Ir/02/PIICC1
AY550178: Leishmania major strain MHOM/Ir/00/PII1
AY573187: Leishmania major strain MHOM/Ir/00/PII2
HM068067: Ferroportin 1 mRNA, Danio rerio (zebrafish)
9